NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
DETECTNET (copper cu 64 dotatate) by Curium Pharma is positron emitting activity [moa]. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DETECTNET (Copper Cu 64 Dotatate) is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It functions as a molecular imaging tool to detect neuroendocrine tumors and other somatostatin receptor-positive lesions. The mechanism leverages copper-64's positron emission for PET imaging combined with dotatate's receptor-targeting specificity.
Peak15.2 years to LOE
Product is at peak commercial penetration with no direct competitors, suggesting stable team size and established market position rather than rapid growth opportunity.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
Neuroendocrine Tumors
Career Relevance
DETECTNET offers stable, specialized career opportunities in a niche diagnostic imaging franchise with established market position and no competitive pressure. Roles are best suited for professionals with oncology/radiology expertise and experience in low-volume, high-value diagnostic products.
Specialty Diagnostic Product Manager
Worked on DETECTNET at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.